When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Ash 2022 preview – Novartis has Apellis in its sights
Iptacopan looks as good as Empaveli in PNH, with the added bonus of being oral.
Pulling back the curtain on Astrazeneca’s Car-T work
Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.
AHA 2022 – Amgen looks good in metabolic disease
With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.
The other shoe drops for Immunic
Failure of a vital catalyst in psoriasis leaves Immunic’s approach at risk of obsolescence.
Bispecifics move beyond cancer
Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.
SITC 2022 preview – cytokines and oral checkpoints
Recently unveiled abstract titles for next month's SITC conference reveal new competition for Incyte’s small-molecule PD-L1 inhibitors.
No big bang for biopharma buyouts
Pfizer's Covid cash keeps the M&A scene alive, but few other developers dug deep in a quiet third quarter.
